|
Post by mnholdem on Sept 10, 2018 12:02:17 GMT -5
Years ago MannKind did have trademarks registered for Coffee Kick and Wine Blast for flavored powders that had no therapeutic benefit.
|
|
|
Post by mnholdem on Sept 10, 2018 10:27:33 GMT -5
falcon said - "I'm not buying until Technosphere is accepted in the marketplace. Afrezza, Treprostinil, Migrane medication, opioid alternative, etc., etc. all deals are great but I want to see sales revenue!" 100 shares now costs $178 ... 100 shares at $200 cost $20,000 ... choose wisely weed hopper! What I'm looking for is confirmation of acceptance in the marketplace. We know Technosphere is a great delivery device. If it can gain acceptance in the marketplace with another molecule then I'll get back in. In other words, "we" know it works but I want to see that "they" know it works? That’s not a bad strategy. Too many of us, myself included, have tried to catch a falling knife with painful results. Years ago, many invested in MNKD thinking that Alfred Mann would sell for multiple times the share price like he did with the MiniMed insulin pump. The expectation of a potentially massive jump in stock price persists for many. Now that MannKind has transitioned from a biotech development company into a pharmaceutical company the dynamics have changed and it’s far more likely that MNKD stock price will make incremental gains based on pivotal events.
|
|
|
Post by mnholdem on Sept 9, 2018 10:47:14 GMT -5
Alfred E. Mann once said that Afrezza could become the biggest blockbuster in history, especially if it becomes the Standard of Care for Type 2 diabetes, which accounts for 90% of diabetes patients. There are many obstacles to overcome but if the science (and MannKind’s CMO) can prevail in 5-10 years to become #1 what value would you place on Afrezza today?
|
|
|
Post by mnholdem on Sept 9, 2018 5:40:57 GMT -5
|
|
|
Post by mnholdem on Sept 8, 2018 17:08:25 GMT -5
Dr Kendall will simultaneously be presenting at the EASD in Germany. I wouldn’t be surprised if Dr Castagna shares some of the findings during his presentation as well.
|
|
|
Post by mnholdem on Sept 8, 2018 17:03:04 GMT -5
We will have the FTC’s decision in three weeks or less. $$$ in the bank 10 days after that if FTC doesn’t nix the deal, which they won’t.
|
|
|
Post by mnholdem on Sept 8, 2018 6:56:36 GMT -5
I have a 65-yo relative who uses the vapor as well as cannabis pills/capsules after his doc cut him off from opioids for chromic back pain from multiple back surgeries and spinal fusions. He simple had to register in Minnesota (~$220 fee) for medical grade cannabis to be legally prescribed by his doctor and his insurance doesn't cover the cost.
|
|
|
Post by mnholdem on Sept 7, 2018 21:40:43 GMT -5
I think the FTC would have a hard time making an anti-trust objection to a deal for a drug/delivery mechanism that has yet to go through Phase 3 trials. Plus, MNKD has no percentage of that market now, only a possibly superior delivery mechanism. I say "possibly" only because it hasn't earned approval as of yet. I also think you are right regarding the additional UTHR interest in other applications. Reading more about Rothblatt, it is clear that she is deeply interested in the subject of organ transplant and even organ manufacturing where there seems to be other possible applications for TI. I like the idea of the UTHR put and think it has real merit. It will be interesting to see just what trials are required for an “already approved drug delivery device” combined with an “already approved drug” ?? Anybody have any ideas on what might be required. 😎 Phase 1 had primary outcomes of safety and tolerability of varying doses. Phase 3 primary outcome will measure effectiveness and no manufacturing certification for the device will be required, since the Dreamboat has already been approved. Future drug-device combinations that involve the Cricket inhaler may require certification of the device but this Phase 3 (TreT/Imodulin) trial will be fairly straightforward and will likely take 4-6 months, IMO.
|
|
|
Post by mnholdem on Sept 7, 2018 21:25:43 GMT -5
The employees have to pay for shares but they dont get to be share holders. Did you mean that employees will be shareholders but with no voting rights?
|
|
|
Post by mnholdem on Sept 7, 2018 21:15:59 GMT -5
Articles are often reprinted in other publications. Of course, they can be submitted but other journals sometimes request permission which helps fill each volume. What I like to see are the words “This article may be reprinted with permission from the author”.
|
|
|
Post by mnholdem on Sept 7, 2018 6:17:57 GMT -5
|
|
|
Post by mnholdem on Sept 6, 2018 14:36:55 GMT -5
In an SEC filing reported August 14, 2018 Goldman Sachs reported that it has divested itself of its remaining 35,000 MNKD Put Contracts during the past 3 months, sending a clear signal to hedge fund managers that it's time to get out of short positions in MannKind Corporation stock (MNKD-NASDAQ).
The Goldman Sachs Group, Inc., is an American multinational investment bank and financial services company headquartered in New York City. It is one of the largest investment banking enterprises in the world. It is a primary dealer in the United States Treasury security market and more generally, a prominent market maker.
The options could of expired or been exercised. Does GS really care that much about a 5M investment in the scheme of their world? At a price of near 1.00 around August 14th, they just may of closed the position for a profit, which is GS MO. for all you know, they may be upside down by 5 Million over the last few days. Nice that longs can sling almost baseless mud. If shareholders seem a little pissed off at Goldman-Sachs it’s likely because the giant investment bank put a target on MannKind with a near-bankruptcy level price target several years ago. I confirmed the SEC filing that G-S got rid of the Puts. Nothing is baseless here except for your accusation.
|
|
|
Post by mnholdem on Sept 6, 2018 14:25:07 GMT -5
I added a screenshot in my original post (WhaleWisdom). I also located the SEC filing itself and confirmed that there are no longer any MNKD Puts listed amongst the GS holdings.
|
|
|
Post by mnholdem on Sept 6, 2018 14:21:24 GMT -5
I added a screenshot in my original post (WhaleWisdom).
|
|
|
Post by mnholdem on Sept 6, 2018 12:08:40 GMT -5
In an SEC filing reported August 14, 2018 Goldman Sachs reported that it has divested itself of its remaining 35,000 MNKD Put Contracts during the past 3 months, sending a clear signal to hedge fund managers that it's time to get out of short positions in MannKind Corporation stock (MNKD-NASDAQ).
The Goldman Sachs Group, Inc., is an American multinational investment bank and financial services company headquartered in New York City. It is one of the largest investment banking enterprises in the world. It is a primary dealer in the United States Treasury security market and more generally, a prominent market maker.
|
|